The European pharmaceutical industry isn’t a faceless entity, it’s a community of more than 100,000 people all working together to improve the lives of people affected by illness.
Because its publicity that money just can’t buy, because it will attract a new breed of investors – and quite simply because it’s the right thing to do.
The factors a doctor should consider when choosing between therapies that could cure patients with skin cancer proved a major talking point at an event on the fringes of this year’s ESMO conference
Within the life science industry, uptake of blockchain is in the early stages, but with investment levels in distributed ledger technology (DLT) on the rise, then it would appear that momentum is b
The National Institute for Health and Care Excellence (NICE) process for single technology appraisals (STA) has been established for many years with clear cost effectiveness thresholds.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
